Sequence: Chol-HHHHHHH-AKRGARSTA
| Experiment Id | EXP000514 |
|---|---|
| Paper | Dual-Blockade Immune Checkpoint for Breast Cancer Treatment Based on a Tumor-Penetrating Peptide Ass |
| Peptide | CHL |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | |
| Rna Concentration | 14 mg/kg (siRNA equivalent) |
| Mixing Ratio | N/P = 20 |
| Formulation Format | self-assembling peptide nanomicelle |
| Formulation Components | CHL, siPD-L1, 1-methyl-DL-tryptophan |
| Size Nm | 175.00 |
| Zeta Mv | 20.00 |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | 4T1 breast cancer allograft (BALB/c mice) |
| Administration Route | intravenous |
| Output Type | tumor growth inhibition / immune activation |
| Output Value | |
| Output Units | |
| Output Notes | Significant tumor suppression and increased CD8+/CD4+ ratio |
| Toxicity Notes | No significant systemic toxicity |
| Curation Notes |